Product
SPH3127
Aliases
SPH3127 matching placebo+valsartan, SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127 tablet
6 clinical trials
5 indications
Indication
Diabetic NephropathyIndication
Ulcerative ColitisIndication
HypertensionIndication
Mild and Moderate HypertensionIndication
ulcerative colitisClinical trial
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential HypertensionStatus: Completed, Estimated PCD: 2023-12-26
Clinical trial
A Clinical Trial to Evaluate Absorption, Metabolism and Excretion of [14C]SPH3127 in Healthy Chinese Adult Male Subjects (Human Mass Balance and Biotransformation Study of [14C]SPH3127)Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy VolunteersStatus: Completed, Estimated PCD: 2018-06-30
Clinical trial
A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-12-01